• Contact us: 01476 247 007
    The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    The Wire – read the latest news from PDS
    16th July 2021

    The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?

    21st July 2021

    Have you appointed your National Contact Person for Pharmacovigilance yet?By 1 January 2022 any European Marketing Authorisation Holders (MAH) who choose to establish a QPPV (Qualified Person for Pharmacovigilance) who resides and operates in the EU/EEA must also nominate a National Contact Person for Pharmacovigilance (NCPP) who resides in the UK and who reports to the QPPV.

    At Pure Drug Safety we know that finding an experienced QPPV can take significant time and money, and with just five months until the end of 2021, the clock is ticking to get a qualified and knowledgeable person in place.

    However, we have the perfect solution for our MAH clients – Pure Drug Safety can be your National Contact Person for Pharmacovigilance from January 2021. Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    PDS will be offering their services to MAH clients as a NCPP from January 2021

    Our NCPP will support and oversee your portfolio and will:

    • have access to the reports of suspected adverse reactions referred to in regulation 187 of the HMRs and the PSMF (pharmacovigilance system master file) for UK authorised products;
    • be able to facilitate responses to pharmacovigilance queries raised by the MHRA, including via inspections;
    • local literature search support;
    • all other actions you require us to carry out from a NCPP perspective here in the UK.

    There has been a temporary exemption in place from 1 January 2021 which gives MAHs 12 months to appoint a National Contact Person for Pharmacovigilance who resides and operates in the UK, but time is now running out fast.

    PDS can be your NCPP and should you appoint us, we will notify the MHRA via the MHRA Submissions Portal.

    Remain compliant in the UK after Brexit

    PDS will be able to help MAHs remain compliant in the UK with a wide range of extra services, in addition to being your NCPP.

    You can read all about how PDS can help you remain compliant in the UK after Brexit on our website here: https://www.puredrugsafety.com/national-contact-person-for-pharmacovigilance/

    So if you need to remain compliant in the UK in readiness for January 1st 2022, email or call us today to discuss your requirements.

    Share

    Related posts

    GCP Inspections: Expectations and the dos and don’ts for hosting
    19th March 2020

    GCP Inspections: Expectations and the dos and don’ts for hosting


    Read more
    Advice for Management of Clinical trials in relation to Coronavirus
    13th March 2020

    Advice for Management of Clinical trials in relation to Coronavirus


    Read more
    NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    17th February 2020

    Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    No Tweets available. Login as Admin to see more details.

    © 2019 - 2022 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA